Rainmed Medical and Sinomedical Enter Strategic Collaboration to Accelerate Precision Medicine in Cardiovascular Care

February 28, 2023,Rainmed Medical (Stock Code: 2297.HK)withSino Medical Sciences Technology Inc. (Stock Code: 688108.SH)A strategic cooperation signing ceremony was held in Beijing. Mr. Huo Yunfei, Chairman of the Board, Executive Director, and Chief Executive Officer of Rainmed Medical, and Mr. Sun Jianhua, Chairman and Chief Executive Officer of Sino Medical Sciences Technology Inc., signed the agreement on behalf of their respective parties. Professor Huo Yong from Peking University First Hospital, and Professor Huo Yunlong, a co-founding shareholder of Rainmed Medical and Professor at the School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, also attended the event.

This timeA High-Tech Hong Kong-Listed Company in the Field of Precision Diagnosis and Treatment of Vascular Diseases in ChinaandA-Share STAR Market Listed Company Specializing in International High-End Interventional Medical Devicesa strong alliance between,"We will fully leverage the respective strengths of both parties in R&D, academia, and marketing to enhance scientific innovation, promote large-scale clinical studies domestically and internationally, increase product visibility, and expand the marketing network.", making the benefits of precision medicine accessible to cardiovascular disease patients worldwide.

RainMed Medical is a national high-tech enterprise. Grounded in the global market, the company emphasizes technological innovation and adheres to independent research and development. Upholding its mission of “Shaping Precision Medicine, Serving Public Health,” RainMed has developed a series of industry-leading functional diagnostic products that have gained extensive clinical recognition. By establishing a comprehensive domestic and international marketing network, RainMed delivers revolutionary diagnostic and therapeutic solutions to patients with vascular diseases worldwide.SinoMedical is a leading enterprise in the treatment of cardiovascular and cerebrovascular diseases. Focusing on scientific research and innovation, the company has cultivated a rich product portfolio and a robust marketing network through years of dedication. Its commercialized products are exported to China, Southeast Asia, South America, and other regions. Pre-market clinical studies for its products under development cover developed countries in Europe and the United States. Notably, SinoMedical is currently the first and only Chinese manufacturer of drug-eluting stents approved to conduct large-scale pre-market confirmatory clinical trials in the United States and Japan.This strategic partnership between RainMed Medical and SinoMedical will leverage their complementary strengths and share resources, propelling the development of precision medicine to new heights!

Professor Huo Yong stated,RainMed Medical and SinoMedical are high-tech medical device companies with exceptional foresight and leadership in the field of cardiovascular disease. As high-quality listed enterprises boasting outstanding innovation capabilities and scientific research proficiency, the strategic partnership between RainMed Medical and SinoMedical is highly anticipated.It is hoped that the strategic partnership between these two companies will generate greater industry value, yield fruitful scientific research outcomes, and ultimately achieve a synergistic effect where 1+1>2. Furthermore, it is expected that both enterprises will continue to strive for excellence, consistently developing innovative products with unique clinical value, thereby driving rapid industry growth and contributing to the prevention and treatment of cardiovascular diseases in China.

Professor Huo Yunlong stated,Since its inception, Runmaide Medical has been deeply rooted in scientific research and innovation, committed to building a globally leading robotic system for vascular interventional surgery.. After eight years of meticulous refinement, the company has achieved a breakthrough by developing and launching the caFFR system with the highest accuracy in China and the globally pioneering caIMR system. These two products are key components of robotic diagnostic systems, offering greater simplicity and efficiency compared to wire-based FFR and wire-based IMR.As a leading enterprise in the field of cardiovascular disease treatment, Sino Medical has a profound scientific research and academic foundation in the industry. It is hoped that this cooperation will promote the upgrading of medical technology and clinical research progress in China, and give full play to the demonstration and leading role of leading enterprises.

President Sun Jianhua stated,Sino Medical aims to build a globally renowned Chinese innovation brand, enhancing the international influence of “Created in China” through continuous research and development of high-quality medical products.To this end, MicroPort continues to expand its product portfolio, launch a series of innovative products, and complete numerous large-scale clinical research projects globally.The caFFR system by Runmaide Medical enables preoperative diagnosis, intraoperative guidance, and postoperative assessment for coronary intervention procedures. Its integration with SinoMedical’s stents will facilitate more scientific diagnostic and therapeutic strategies in clinical practice. This collaboration is poised to elevate industry standards and benefit countless patients with cardiovascular diseases.

Also in attendance at the strategic cooperation signing ceremony were Ms. Feng Yundi, Medical Director of Rainmed Medical; Mr. Xia Kefu, Director of International Marketing at Rainmed Medical; Ms. Mu Rui, Deputy Sales Director of Rainmed Medical; Mr. Huang Kai, Director and Board Secretary of Sino Medical Sciences Technology Inc.; and Mr. Miao Xiangfei, Director of Business Development and International Marketing at Sino Medical Sciences Technology Inc.

RainMed Medical Group, founded in 2014, is a leading enterprise in the precise diagnosis and treatment of cardiovascular diseases. In July 2022, RainMed Medical was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited, with the stock code 2297.HK. Established by returning scholars and top industry technicians, the company adheres to independent innovation and dedicated R&D, creating and launching a series of globally leading, epoch-making products for cardiovascular diagnosis and treatment. RainMed Medical has established a global network for R&D, manufacturing, sales, and services. Its products are available in major hospitals across China, and the company conducts business cooperation with more than 10 countries and regions worldwide. Remaining true to its original aspiration and persevering, RainMed Medical continuously expands the scope of product applications and enhances clinical value, pioneering a new era for precision medicine in the field of interventional cardiology.

Sino Medical Sciences Technology Inc. (SinoMed) was founded in 2007 and has established wholly-owned subsidiaries in Beijing, Suzhou, Hong Kong, the United States, Japan, the Netherlands, and France. In October 2019, the company was listed on the Shanghai Stock Exchange’s STAR Market (stock code: 688108.SH). Committed to independent innovation, strict quality control, and internationalization, SinoMed is dedicated to advancing the development of interventional technology in China, creating high-quality medical products, and enhancing the global influence of “Created in China.” After more than a decade of development, SinoMed has initially established an R&D, manufacturing, and operational system with international standards. Its business covers key areas of interventional therapy, including cardiovascular, cerebrovascular, and structural heart diseases. To date, cumulative usage of SinoMed’s core products—such as coronary drug-eluting stents, coronary balloons, and intracranial rapid-exchange balloons—has exceeded 1.3 million units. These products are used in over 2,000 hospitals, benefiting hundreds of thousands of patients across China, Southeast Asia, and South America.